David Calvet Canut։ Efdoralprin Alfa Shows Promise in Alpha 1 Antitrypsin Deficiency
David Calvet Canut, Chief Financial Officer at Rudder Marine Services and Ship Repairs S.L, shared a post on LinkedIn:
”A potential breakthrough for Alpha-1 Antitrypsin Deficiency (AATD) has emerged from Sanofi’s Phase 2 ElevAATe clinical trial.
The investigational treatment, efdoralprin alfa, has shown promising results for adults living with pulmonary emphysema caused by AATD.
Unlike current therapies that rely on donated plasma, efdoralprin alfa is a recombinant protein produced in the laboratory, designed to mimic the natural AAT protein that protects the lungs from inflammatory damage.
This could represent a significant advancement towards a more sustainable, supply-independent treatment option.
Key findings from the ElevAATe trial include:
- Patients achieved normal, stable levels of functional AAT protein, significantly higher than those seen with standard plasma-derived treatment.
- A greater proportion of days were spent at protective protein levels.
- The treatment was well tolerated, with a safety profile comparable to existing therapies.
- It is effective when administered every three to four weeks, potentially offering a more convenient treatment schedule.
Dr. Igor Barjaktarevic, lead investigator at UCLA, noted that achieving normal AAT levels without relying on plasma donations ‘would be a very positive change’ for patients living with Alpha-1.
Efdoralprin alfa has already received both Fast Track and Orphan Drug designations from the FDA, indicating the unmet need this treatment aims to address.
A long-term safety follow-up study (ElevAATe OLE) is now underway.”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 23:39Paul Tortland: What a New PRP Study Really Tells Us About Knee Osteoarthritis
-
Oct 28, 2026, 23:34Jawad Derbas: Comparing Mechanical and Pharmacomechanical VTE Prophylaxis in Spine Surgery
-
Oct 28, 2026, 23:31Giulio Maria Pasinetti: Aspirin Use Linked to Lower Dementia Risk in Older Adults With Specific Genetic Characteristics
-
Oct 28, 2026, 23:27Ralf Ludwig: Targeting Neutrophil-Driven Autoimmunity Through CDK Inhibition
-
Oct 28, 2026, 23:26Houda Moustaide: Great Discussions During Our Training Day on Thrombocytopenia in Pregnancy
-
Oct 28, 2026, 23:22Keith Berelowitz: Building Better Medicines by Listening to Patients With Bleeding Disorders
-
Oct 28, 2026, 23:19Nickie Enos: Blood Clots in Arteries and Veins Differ in Symptoms and Treatment
-
Oct 28, 2026, 23:17David Rosenblum: Can Concentrated PRP Actually Cause Scar Tissue?
-
Oct 28, 2026, 23:15Shueh Hao Lim: Advancing Multidisciplinary Care for Venous Thromboembolism in Malaysia